FDA launches crackdown on deceptive drug advertising
The FDA is beginning rulemaking to close the “adequate provision” loophole
The FDA is beginning rulemaking to close the “adequate provision” loophole
Cagrilintide represents a novel approach to obesity management
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Maria Soler Nunez appointed as Chief Quality Officer
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Subscribe To Our Newsletter & Stay Updated